Recombinant Zebrafish ADAT2
Cat.No. : | ADAT2-5392Z |
Product Overview : | Recombinant Zebrafish ADAT2 full length or partial length protein was expressed. |
- Specification
- Gene Information
- Related Products
Source : | Mammalian Cells |
Species : | Zebrafish |
Tag : | His |
Form : | Liquid or lyophilized powder |
Endotoxin : | < 1.0 eu per μg of the protein as determined by the LAL method. |
Purity : | >80% |
Notes : | This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications. |
Storage : | Store it at +4 oC for short term. For long term storage, store it at -20 oC~-80 oC. |
Storage Buffer : | PBS buffer |
Gene Name : | adat2 adenosine deaminase, tRNA-specific 2, TAD2 homolog (S. cerevisiae) [ Danio rerio (zebrafish) ] |
Official Symbol : | ADAT2 |
Gene ID : | 100034610 |
mRNA Refseq : | NM_001083097 |
Protein Refseq : | NP_001076566 |
UniProt ID : | B3DKA9 |
Products Types
◆ Recombinant Protein | ||
Adat2-1536M | Recombinant Mouse Adat2 Protein, Myc/DDK-tagged | +Inquiry |
ADAT2-2507H | Recombinant Human ADAT2 Protein, GST-tagged | +Inquiry |
ADAT2-331M | Recombinant Mouse ADAT2 Protein, His (Fc)-Avi-tagged | +Inquiry |
ADAT2-1142H | Recombinant Human ADAT2 Protein, MYC/DDK-tagged | +Inquiry |
ADAT2-1334M | Recombinant Mouse ADAT2 Protein | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (12)
Ask a questionOne limitation of using ADAT2 protein in medicine is the potential off-target effects of RNA editing. RNA editing is a complex process, and manipulating ADAT2 could potentially result in unintended changes to RNA molecules that could cause harmful effects. Additionally, the specificity and efficacy of RNA editing therapies are still being studied, and more research is needed to understand how precisely ADAT2 and related proteins can target specific RNA sequences.
As of now, there are no clinical trials specifically investigating ADAT2 protein. However, RNA editing and the ADAR enzyme complex are active areas of research for potential therapeutic applications in various diseases. As such, it is possible that ADAT2 and other components of the ADAR enzyme complex may be investigated in clinical trials in the future.
Yes, ADAT2 protein has been implicated in several diseases or disorders. For example, mutations in ADAT2 have been associated with certain neurological disorders, such as Amyotrophic lateral sclerosis (ALS) and Frontotemporal dementia with motor neuron disease (FTD-MND). Additionally, abnormalities in RNA editing have been linked to various types of cancer, and ADAT2 is thought to play a role in the dysregulation of RNA editing in certain types of cancer.
There may be commercial applications for manipulating ADAT2 protein in the development of RNA editing therapies and diagnostics for diseases that involve RNA editing defects. Additionally, there may be applications for ADAT2 in basic research on RNA editing and related processes. However, more research is needed to fully understand the potential commercial applications of manipulating ADAT2 protein.
Yes, any medical or commercial applications of manipulating ADAT2 protein would be subject to regulatory oversight. Gene therapy and RNA editing technologies are subject to rigorous safety and efficacy testing before they can be approved for clinical use by regulatory agencies such as the FDA in the United States. Additionally, commercial applications of manipulating ADAT2 could be subject to patent law and other intellectual property regulations.
Yes, ADAT2 protein could potentially be a target for developing new drugs. As dysregulation of RNA editing is increasingly recognized as an important factor in various diseases, ADAT2 could be targeted to develop drugs that modulate RNA editing. By regulating RNA editing, it may be possible to correct underlying genetic defects and treat diseases such as cancer or neurodegenerative disorders.
ADAT2 protein is produced through transcription and translation of the ADAT2 gene. The gene encodes the ADAT2 protein, which is then formed through folding of its amino acid sequence. ADAT2 is a member of the family of tRNA-specific adenosine deaminase (tadA) enzymes and shares homology with other members of this family. The crystal structure of ADAT2 has been solved which shows that its active site is composed of two subunits, ADAT2 and ADAT3, which work together to modify RNA transcripts.
There are no known human diseases specifically caused by mutations or deficiencies in ADAT2 protein. However, as ADAT2 is a component of the ADAR enzyme complex which is involved in RNA editing, defects in RNA editing have been linked to a variety of diseases such as neurological disorders, autoimmune diseases, and cancers. Therefore, defects in ADAR complex components, including ADAT2, may also contribute to these disease states.
ADAT2 protein has potential applications in medical research, specifically related to RNA editing. In some studies, ADAT2 has been shown to be a critical component of the RNA editing machinery that is important for diseases such as cancer and epilepsy. Researchers are working to develop therapies that modulate RNA editing to treat these diseases, and ADAT2 may be a potential target for these therapies.
To date, there are no known diseases or conditions in which ADAT2 protein has been shown to be a useful biomarker. However, as research into RNA editing and its role in disease progresses, it is possible that ADAT2 or other components of the ADAR enzyme complex may be found to serve as biomarkers for certain diseases or conditions.
Manipulating ADAT2 protein could have various medical applications due to its role in regulating RNA editing. RNA editing has been implicated in neurological disorders, such as epilepsy and schizophrenia, and manipulating ADAT2 could provide a way to restore proper RNA editing and potentially improve symptoms. Additionally, RNA editing has been shown to play a role in cancer development and progression, and targeted manipulation of ADAT2 could help to correct RNA editing defects in cancer cells and improve the efficacy of existing therapies. Further research is needed to understand the full potential of manipulating ADAT2 in medicine.
Yes, ADAT2 protein manipulation could be used as part of gene therapy. Gene therapy involves introducing genetic material into cells to treat or prevent disease, and RNA editing is one potential application of gene therapy. Manipulating ADAT2 could provide a precise way to target specific RNA sequences and correct genetic mutations that cause disease. However, further research on the safety and efficacy of gene therapy is needed before it can be widely used as a treatment option.
Ask a Question for All ADAT2 Products
Required fields are marked with *
My Review for All ADAT2 Products
Required fields are marked with *
Inquiry Basket